These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 28981166)

  • 1. Terlipressin: Current and emerging indications in chronic liver disease.
    Papaluca T; Gow P
    J Gastroenterol Hepatol; 2018 Mar; 33(3):591-598. PubMed ID: 28981166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis.
    Narahara Y; Kanazawa H; Taki Y; Kimura Y; Atsukawa M; Katakura T; Kidokoro H; Harimoto H; Fukuda T; Matsushita Y; Nakatsuka K; Sakamoto C
    J Gastroenterol Hepatol; 2009 Nov; 24(11):1791-7. PubMed ID: 19686420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting circulatory dysfunction in cirrhosis: terlipressin and the hepatorenal syndrome.
    Testro AG; Angus PW
    J Gastroenterol Hepatol; 2009 Nov; 24(11):1707-9. PubMed ID: 20136956
    [No Abstract]   [Full Text] [Related]  

  • 4. Hemodynamic effects of a combination of octreotide and terlipressin in patients with viral hepatitis related cirrhosis.
    Lin HC; Yang YY; Hou MC; Huang YT; Lee WC; Lee FY; Chang FY; Lee SD
    Scand J Gastroenterol; 2002 Apr; 37(4):482-7. PubMed ID: 11989841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of perioperative terlipressin infusion on systemic, hepatic, and renal hemodynamics during living donor liver transplantation.
    Fayed N; Refaat EK; Yassein TE; Alwaraqy M
    J Crit Care; 2013 Oct; 28(5):775-82. PubMed ID: 23618777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of somatostatin, terlipressin and somatostatin plus terlipressin on portal and systemic hemodynamics and renal sodium excretion in patients with cirrhosis.
    Kalambokis G; Economou M; Paraskevi K; Konstantinos P; Pappas C; Katsaraki A; Tsianos EV
    J Gastroenterol Hepatol; 2005 Jul; 20(7):1075-81. PubMed ID: 15955217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison.
    Baik SK; Jeong PH; Ji SW; Yoo BS; Kim HS; Lee DK; Kwon SO; Kim YJ; Park JW; Chang SJ; Lee SS
    Am J Gastroenterol; 2005 Mar; 100(3):631-5. PubMed ID: 15743362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of terlipressin and somatostatin on liver and thorax blood volumes in patients with cirrhosis.
    Kalambokis G; Tsiouris S; Tsianos EV; Baltayiannis G; Pakou B; Fotopoulos A
    Liver Int; 2010 Oct; 30(9):1371-8. PubMed ID: 20738780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome.
    Krag A; Borup T; Møller S; Bendtsen F
    Adv Ther; 2008 Nov; 25(11):1105-40. PubMed ID: 19018483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemodynamic effects of terlipressin and high somatostatin dose during acute variceal bleeding in nonresponders to the usual somatostatin dose.
    Villanueva C; Planella M; Aracil C; López-Balaguer JM; González B; Miñana J; Balanzó J
    Am J Gastroenterol; 2005 Mar; 100(3):624-30. PubMed ID: 15743361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.
    Martín-Llahí M; Pépin MN; Guevara M; Díaz F; Torre A; Monescillo A; Soriano G; Terra C; Fábrega E; Arroyo V; Rodés J; Ginès P;
    Gastroenterology; 2008 May; 134(5):1352-9. PubMed ID: 18471512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome.
    Hadengue A; Gadano A; Moreau R; Giostra E; Durand F; Valla D; Erlinger S; Lebrec D
    J Hepatol; 1998 Oct; 29(4):565-70. PubMed ID: 9824265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemodynamic and metabolic effects of terlipressin in patients with cirrhosis receiving a nonselective beta-blocker.
    Vachiery F; Moreau R; Gadano A; Yang S; Sogni P; Hadengue A; Cailmail S; Soupison T; Lebrec D
    Dig Dis Sci; 1996 Sep; 41(9):1722-6. PubMed ID: 8794785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ischemic skin necrosis following terlipressin therapy: report of two cases and review of the literature.
    Taşliyurt T; Kutlutürk F; Erdemır F; Yelken BM; Yilmaz A; Kisacik B; Aytan P; Köseoğlu RD
    Turk J Gastroenterol; 2012; 23(6):788-91. PubMed ID: 23864457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology, clinical efficacy and safety of terlipressin in esophageal varices bleeding, septic shock and hepatorenal syndrome.
    Saner FH; Canbay A; Gerken G; Broelsch CE
    Expert Rev Gastroenterol Hepatol; 2007 Dec; 1(2):207-17. PubMed ID: 19072411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemodynamic effects of continuous versus bolus infusion of terlipressin for portal hypertension: a randomized comparison.
    Ding C; Wu X; Fan X; He C; Li J
    J Gastroenterol Hepatol; 2013 Jul; 28(7):1242-6. PubMed ID: 23489113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of terlipressin on blood volume distribution in patients with cirrhosis.
    Kiszka-Kanowitz M; Henriksen JH; Hansen EF; Møller S; Bendtsen F
    Scand J Gastroenterol; 2004 May; 39(5):486-92. PubMed ID: 15180188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Terlipressin, a vasoactive prodrug recommended in hepatorenal syndrome, is an agonist of human V1, V2 and V1B receptors: Implications for its safety profile.
    Colson PH; Virsolvy A; Gaudard P; Charrabi A; Corbani M; Manière MJ; Richard S; Guillon G
    Pharmacol Res; 2016 Nov; 113(Pt A):257-264. PubMed ID: 27586252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of different therapeutic modalities on systemic, renal, and hepatic hemodynamics and short-term outcomes in cirrhotic patients with spontaneous bacterial peritonitis.
    Salman TA; Edrees AM; El-Said HH; El-Abd OL; El-Azab GI
    Eur J Gastroenterol Hepatol; 2016 Jul; 28(7):777-85. PubMed ID: 27097354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Terlipressin in hepatorenal syndrome: Evidence for present indications.
    Rajekar H; Chawla Y
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():109-14. PubMed ID: 21199521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.